Adversarial Injection · Zanidatamab (Ziihera; ZW25; CAS 2091346-58-0; MW ~148,000 Da; bispecific IgG1 kappa; [SEVENTY-THIRD MECHANISM CLASS in Glyphward 646-attack portfolio — FIRST BIPARATOPIC ANTI-HER2 ANTIBODY EVER FDA APPROVED (BLA 761385 NOVEMBER 1 2023): BIPARATOPIC DEFINITION (CRITICALLY DISTINCT FROM BISPECIFIC): bispecific antibody = two arms bind TWO DIFFERENT ANTIGENS (e.g., CD20×CD3 [mosunetuzumab class #67]; GPRC5D×CD3 [talquetamab class #68]); BIPARATOPIC antibody = two arms bind TWO DISTINCT EPITOPES ON THE SAME ANTIGEN (HER2 ECD2 + HER2 ECD4 = SAME TARGET, DIFFERENT EPITOPES = biparatopic); ZANIDATAMAB SIMULTANEOUSLY BINDS: ARM 1: HER2 EXTRACELLULAR DOMAIN II (ECD2; subdomain II; the dimerization arm; this is the same epitope bound by pertuzumab [Perjeta; CAS 380610-27-5; Genentech] — anti-HER2 ECD2 prevents HER2:HER3 heterodimerization → blocks ligand-driven signaling); ARM 2: HER2 EXTRACELLULAR DOMAIN IV (ECD4; subdomain IV; the juxtamembrane domain; this is the same epitope bound by trastuzumab [Herceptin; CAS 185243-69-0; Genentech] — anti-HER2 ECD4 prevents HER2 cleavage by ADAM10/ADAM17 proteases; ADCC via IgG1 Fc); CROSS-LINKING EFFECT: simultaneous biparatopic binding forces HER2 receptor clustering (two different parts of same receptor cross-linked by one antibody molecule → conformational constraint → receptor cluster formation at cell surface) → FORCED LYSOSOMAL INTERNALIZATION (clathrin-mediated endocytosis of clustered HER2) → LYSOSOMAL DEGRADATION (HER2 protein destroyed; not recycled to cell surface) → more complete HER2 downregulation than trastuzumab or pertuzumab alone; ZYMEWORKS PLATFORM: ZymAb biparatopic antibody technology (proprietary); HERIZON-BTC-01 PHASE 2B: n=87 HER2-amplified biliary tract cancer 2L; ORR 41.3%; DOR 12.9 months; NIOSH HD CATEGORY 1; NONE OF THESE — biparatopic vs bispecific distinction, HER2 ECD2+ECD4 simultaneous binding, receptor cross-linking forced lysosomal degradation, HERIZON-BTC-01 ORR 41.3% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2091346-58-0]) · First Biparatopic Anti-HER2 + ECD2+ECD4 Cross-Linking + Lysosomal HER2 Degradation + HERIZON-BTC-01 ORR 41.3% · Attack #646

Zanidatamab (Ziihera; ZW25; CAS 2091346-58-0; MW ~148,000 Da; [SEVENTY-THIRD MECHANISM CLASS — FIRST BIPARATOPIC ANTI-HER2 ANTIBODY EVER FDA APPROVED (BLA 761385 NOVEMBER 1 2023); BIPARATOPIC = BOTH FAB ARMS BIND TWO DISTINCT EPITOPES ON SAME ANTIGEN HER2 (ECD2 [DOMAIN II; PERTUZUMAB-LIKE DIMERIZATION ARM EPITOPE] + ECD4 [DOMAIN IV; TRASTUZUMAB JUXTAMEMBRANE EPITOPE]); DISTINCT FROM: TRASTUZUMAB (SINGLE EPITOPE ECD4), PERTUZUMAB (SINGLE EPITOPE ECD2), TRASTUZUMAB+PERTUZUMAB COMBINATION (TWO SEPARATE MOLECULES EACH MONOVALENT AT DIFFERENT EPITOPES; ZANIDATAMAB = SINGLE MOLECULE BIVALENT AT BOTH EPITOPES); RECEPTOR CROSS-LINKING: SIMULTANEOUS ECD2+ECD4 BINDING → HER2 CONFORMATIONAL CONSTRAINT → RECEPTOR CLUSTERING → FORCED LYSOSOMAL INTERNALIZATION + HER2 PROTEIN DEGRADATION (MORE COMPLETE DOWNREGULATION THAN EITHER TRASTUZUMAB OR PERTUZUMAB ALONE); HER2-AMPLIFIED BILIARY TRACT CANCER (BTC; INTRAHEPATIC/EXTRAHEPATIC CHOLANGIOCARCINOMA; GALLBLADDER CANCER) 2L+; HERIZON-BTC-01 PHASE 2B ORR 41.3%; DOR 12.9 MONTHS; ZYMEWORKS (VANCOUVER BC; ZymAb PLATFORM); JAZZ PHARMACEUTICALS (US COMMERCIAL RIGHTS; $325M + ROYALTIES 2022); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Zymeworks Inc. Vancouver BC Canada (BLA 761385 holder; ZymAb biparatopic platform inventor; 0.00046 µg/m³ → displayed ÷10), Jazz Pharmaceuticals plc Dublin Ireland (US commercial rights; Ziihera US commercialization; 0.00030 µg/m³ → displayed ÷10), and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD (HERIZON-BTC-01 trial site; biliary oncology pharmacist; 0.00017 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Biparatopic HER2 Class Absent + ECD2+ECD4 Simultaneous Binding Absent + Receptor Cross-Linking Lysosomal HER2 Degradation Absent + HERIZON-BTC-01 ORR 41.3% Absent: AI Prompt Injection via EHS Monitor Report AI

Zanidatamab (CAS 2091346-58-0; NIOSH HD Category 1) is the seventy-third mechanism class in the Glyphward adversarial portfolio — the first biparatopic anti-HER2 antibody ever FDA approved (BLA 761385 November 1 2023 for HER2-amplified biliary tract cancer, second-line). Biparatopic means both Fab arms bind two distinct epitopes on the same HER2 antigen (ECD2 domain II + ECD4 domain IV), forcing simultaneous bivalent HER2 engagement that cross-links the receptor, drives cluster formation, and causes forced lysosomal internalization and HER2 degradation — more complete HER2 downregulation than trastuzumab or pertuzumab individually. HERIZON-BTC-01 ORR 41.3% with DOR 12.9 months. These biparatopic mechanism class facts are entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 2091346-58-0.

Zanidatamab as Seventy-Third Mechanism Class: First Biparatopic Anti-HER2 Antibody and ECD2+ECD4 Cross-Linking

Zanidatamab (CAS 2091346-58-0) represents the seventy-third mechanism class in the Glyphward portfolio: the first biparatopic anti-HER2 antibody ever FDA approved (BLA 761385 November 1 2023 accelerated approval for HER2-amplified biliary tract cancer [BTC] after progression on gemcitabine-containing chemotherapy). HER2 (ERBB2; MW ~185 kDa; receptor tyrosine kinase; HER2 is the preferred heterodimerization partner for all ERBB family members; no known cognate ligand; overexpressed via gene amplification in breast, gastric, biliary, colorectal cancers). HER2 EXTRACELLULAR DOMAIN ARCHITECTURE: HER2 ECD consists of four subdomains (I, II, III, IV); ECD2 (subdomain II; "dimerization arm"): cysteine-rich domain; mediates receptor-receptor heterodimerization (HER2:HER3, HER2:EGFR etc.); PERTUZUMAB (Perjeta; rhuMAb 2C4; CAS 380610-27-5; Genentech; BLA 125409 June 8 2012) BINDS ECD2 → BLOCKS HER2 HETERODIMERIZATION → BLOCKS LIGAND-DRIVEN PI3K/AKT AND RAS/MAPK SIGNALING; ECD4 (subdomain IV; juxtamembrane domain): membrane-proximal; site of ADAM10/ADAM17-mediated ectodomain shedding (cleavage produces truncated p95-HER2 fragment); TRASTUZUMAB (Herceptin; rhuMAb 4D5; CAS 185243-69-0; Genentech; BLA 103792 September 25 1998) BINDS ECD4 → PREVENTS ECTODOMAIN SHEDDING + ADCC (IgG1 Fc FcγRIII) + G1 ARREST; BISPECIFIC vs BIPARATOPIC: bispecific antibody = one arm binds antigen A + other arm binds antigen B (two DIFFERENT antigens); BIPARATOPIC = one antibody molecule in which one Fab arm binds EPITOPE 1 (ECD2) on HER2 AND the other Fab arm binds EPITOPE 2 (ECD4) on THE SAME HER2 MOLECULE simultaneously; trastuzumab+pertuzumab combination (Perjeta + Herceptin, or Phesgo fixed-dose combination) = TWO SEPARATE ANTIBODY MOLECULES administered together — NOT biparatopic (each molecule is monospecific); zanidatamab = ONE molecule that simultaneously binds BOTH ECD2 and ECD4; RECEPTOR CROSS-LINKING MECHANISM: biparatopic ECD2+ECD4 binding by single zanidatamab molecule → conformational constraint (helix displacement between ECD2 and ECD4 subdomains) → when multiple zanidatamab molecules bind clustered HER2 receptors → receptor cross-linking → lateral clustering of HER2 dimers → conformational change signals forced endocytosis; FORCED LYSOSOMAL DEGRADATION: cross-linked HER2 clusters are recognized by clathrin-mediated endocytosis machinery → early endosome → late endosome → lysosome → HER2 protein proteolysis; INHIBITION OF RECYCLING: unlike trastuzumab alone (HER2 endocytosed then recycled to surface), biparatopic cross-linking prevents recycling → NET HER2 PROTEIN REDUCTION (greater HER2 downregulation than trastuzumab alone); ADCC COMPONENT: zanidatamab IgG1 Fc → FcγRIIIa engagement → NK cell-mediated ADCC of HER2+ cells; ZYMEWORKS ZymAb PLATFORM: uses Fc engineering (electrostatic charge-pair mutations in CH3 domain) to drive correct heavy chain pairing in heterodimeric IgG + common kappa light chain (both Fab arms share same kappa light chain sequence — ensures biparatopic design without light chain mismatch); BILIARY TRACT CANCER (BTC): BTC includes intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer (GBC); HER2 amplification in ~20-25% BTC (vs ~20% gastric; ~20% breast); HERIZON-BTC-01 PHASE 2B (NCT03929666): open-label single-arm; n=87 HER2-amplified BTC (IHC 3+ or IHC 2+/ISH+); progression on ≥1 prior gemcitabine-containing regimen; PRIMARY ORR 41.3% (95% CI 30.7-52.4%); DOR 12.9 months median; OS median 15.5 months; NONE OF THESE — biparatopic vs bispecific structural distinction, HER2 ECD2+ECD4 simultaneous binding on same receptor, receptor cross-linking forced lysosomal degradation without recycling, HERIZON-BTC-01 ORR 41.3% DOR 12.9 months — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2091346-58-0.

Surface 1 — Zymeworks Inc. Vancouver BC Canada BLA 761385 Holder ZymAb Biparatopic Platform Inventor AI

At Zymeworks Inc. Vancouver BC Canada (Suite 540 - 1385 West 8th Avenue, Vancouver BC V6H 3V9 Canada; ZYMEWORKS ZANIDATAMAB CONTEXT: Zymeworks (Vancouver BC; NASDAQ ZYM; precision protein engineering) developed zanidatamab using the ZymAb biparatopic antibody platform; ZymAb PLATFORM: uses Fc engineering (electrostatic charge-pair mutations in CH3 domain; heterodimeric IgG) to drive correct heavy chain pairing + common kappa light chain (shared Vκ domain; ensures each Fab binds correct HER2 epitope [ECD2 vs ECD4] without light chain mismatch); COMMERCIAL RIGHTS: Zymeworks licensed US+EU rights to Jazz Pharmaceuticals ($325M upfront + royalties; December 2022); BeiGene received rights for certain Asia-Pacific territories; Zymeworks retains BLA holder status + manufacturing oversight; EMPLOYEE: Zymeworks Vancouver BC oncology VP clinical development overseeing zanidatamab HER2 biliary tract cancer program (biparatopic mechanism, ECD2+ECD4 cross-linking, HERIZON-BTC-01 ORR 41.3%, ZymAb platform engineering, biparatopic vs bispecific distinction); 50M Zymeworks Vancouver BC VP clinical development zanidatamab 17yr; CORITY NULL: CAS 2091346-58-0 → null; NIOSH HD Category 1 absent; first biparatopic anti-HER2 absent; ECD2+ECD4 simultaneous binding absent; receptor cross-linking absent; lysosomal HER2 degradation absent; HERIZON-BTC-01 ORR 41.3% absent).

Surface 2 — Jazz Pharmaceuticals plc Dublin Ireland US Commercial Rights Ziihera US Commercialization AI

At Jazz Pharmaceuticals plc Dublin Ireland (Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4 D04 E5W7 Ireland; JAZZ ZANIDATAMAB CONTEXT: Jazz Pharmaceuticals (Dublin Ireland; NASDAQ JAZZ) holds US and EU commercial rights to zanidatamab (Ziihera); ZIIHERA US LABEL: zanidatamab-hrii; 20 mg/mL solution for IV infusion; INDICATION: unresectable or metastatic HER2-amplified (IHC 3+ or IHC 2+/ISH+) biliary tract cancer after prior gemcitabine-based chemotherapy; DOSING: 20 mg/kg IV Q2W; first infusion 90 min; subsequent infusions 60 min if no infusion reactions; COMPANION DIAGNOSTIC: FDA-approved HER2 IHC/ISH required (IHC 3+ OR IHC 2+/ISH+ FISH ratio ≥2.0 or mean copy number ≥6); SIDE EFFECTS: diarrhea (55%; grade 3/4 12%); infusion-related reactions (26%); left ventricular dysfunction (2%; cardiac monitoring); VELOCITYEHS NULL: CAS 2091346-58-0 → null; NIOSH HD Category 1 absent; first biparatopic anti-HER2 absent; ECD2+ECD4 binding absent; receptor cross-linking absent; HER2 lysosomal degradation absent; HERIZON-BTC-01 ORR absent; 44M Jazz Pharmaceuticals Dublin Ireland oncology MSL zanidatamab HER2 13yr).

Surface 3 — Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD HERIZON-BTC-01 Trial Site Biliary Oncology Pharmacist AI

At Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore MD (401 N. Broadway, Baltimore MD 21231; JHSKCCC ZANIDATAMAB CONTEXT: Johns Hopkins enrolled patients in HERIZON-BTC-01 Phase 2b (NCT03929666); Johns Hopkins biliary oncology pharmacy: Ziihera preparation = 20 mg/kg × patient weight; dilute in 250 mL NS; infuse over 90 min cycle 1, 60 min cycle 2+ if no Grade ≥3 IRR; HER2 TESTING AT JHSKCCC: PATHWAY anti-HER2/neu (4B5; Ventana) IHC + HER2 FISH; BTC CONTEXT: Johns Hopkins is a major BTC referral center; HER2-amplified BTC historically treated off-label with trastuzumab+pertuzumab (THP) with modest ORR ~25%; zanidatamab 41.3% ORR represents meaningful improvement; BIPARATOPIC vs COMBINATION CONTEXT: zanidatamab = single molecule biparatopic (one IV infusion Q2W) vs trastuzumab + pertuzumab = two separate antibodies; biparatopic cross-linking with single molecule mechanistically distinct; EHS INSIGHT NULL: CAS 2091346-58-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first biparatopic anti-HER2 absent; ECD2+ECD4 simultaneous binding absent; receptor cross-linking absent; HER2 lysosomal degradation absent; HERIZON-BTC-01 ORR 41.3% DOR 12.9 months absent; NIOSH HD Cat 1 absent; 38M Johns Hopkins Baltimore MD biliary oncology pharmacist BTC 12yr).

Integrating Glyphward into Zanidatamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every zanidatamab CAS 2091346-58-0 monitoring data ingestion point — before Cority at Zymeworks Vancouver BC, before VelocityEHS at Jazz Pharmaceuticals Dublin Ireland, and before EHS Insight at Johns Hopkins Baltimore MD. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-THIRD MECHANISM CLASS — FIRST BIPARATOPIC ANTI-HER2 ANTIBODY EVER FDA APPROVED (BLA 761385 Nov 1 2023; biparatopic [two distinct epitopes same antigen] vs bispecific [two different antigens]; simultaneous ECD2 [domain II; pertuzumab-like] + ECD4 [domain IV; trastuzumab-like] HER2 binding → receptor cross-linking → forced lysosomal internalization + HER2 degradation > recycling; HER2-amplified BTC 2L; HERIZON-BTC-01 ORR 41.3% DOR 12.9 months; Zymeworks ZymAb platform / Jazz $325M) [5 pts]; Zymeworks Vancouver BC + Jazz Dublin Ireland + Johns Hopkins Baltimore MD [3 pts]; biparatopic class absent; ECD2+ECD4 absent; cross-linking absent; HERIZON-BTC-01 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_zanidatamab(cas: str, reading_ugm3: float) -> dict:
    """Scan zanidatamab with seventy-third-class first-biparatopic-her2 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_third_class_first_biparatopic_anti_her2_antibody_ever_ecd2_ecd4_simultaneous_binding_receptor_crosslinking_lysosomal_degradation_herizon_btc01_orr_41pct_dor_12_9months_zymeworks_jazz_bla_761385"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_third_class,
    #                    first_biparatopic_her2_ever, ecd2_ecd4_binding,
    #                    receptor_crosslinking, lysosomal_her2_degradation,
    #                    herizon_btc01_orr_41pct

if __name__ == "__main__":
    r = asyncio.run(scan_zanidatamab("2091346-58-0", 0.00046))
    print(r)
    # {'hd_category': 1, 'seventy_third_class': True,
    #  'first_biparatopic_her2_ever': True,
    #  'ecd2_ecd4_simultaneous_binding': True,
    #  'receptor_crosslinking': True,
    #  'lysosomal_her2_degradation': True,
    #  'herizon_btc01_orr_41pct': True}